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OBJECTIVES To determine the influence of clinical practice guidelines on treatment patterns and clinical
outcomes in unstable angina and the effectiveness of guideline reminders on implementing
practice guidelines, two groups of medium and high risk patients with unstable angina were
compared.
BACKGROUND New guidelines have been published by the Agency for Health Care Policy and Research
(AHCPR) for evaluating and managing patients with unstable angina. The impact of these
guidelines to improve the quality of care has never been tested.
METHODS Group 1 included 338 consecutive medium or high risk patients admitted before publication
of the AHCPR guidelines, and group 2 consisted of 181 consecutive similar risk patients
admitted after institution of the AHCPR guideline reminders at this institution. Dissemi-
nation of clinical practice guidelines was ensured by a grand rounds lecture and by posting
guideline reminders on all group 2 patients’ charts within 24 h of admission.
RESULTS The two groups were similar in terms of most baseline characteristics, including hypercho-
lesterolemia, diabetes, hypertension, smoking history, baseline ST segment depression and
previous coronary artery bypass graft surgery. Group 1 patients were older (68 6 13 vs. 63 6
16 years, p 5 0.001) and more frequently had a previous myocardial infarction (39% vs. 22%,
p 5 0.001). Group 2 patients more frequently required intravenous nitroglycerin to control
the index episode of chest pain (43% vs. 34%, p 5 0.003). Group 2 patients more frequently
received aspirin (96% vs. 88%, p 5 0.009) during admission and underwent coronary
angiography (71% vs. 58%, p 5 0.006). More importantly, group 2 patients received oral
beta-blockers (p 5 0.008), aspirin and coronary angiography (p 5 0.001) earlier than group
1 patients and experienced recurrent angina (29% vs. 54%) and myocardial infarction or death
less frequently (3% vs. 9%, p 5 0.028).
CONCLUSIONS In unstable angina, clinical practice guidelines were associated with greater use of aspirin and
coronary angiography and greater use and earlier administration of beta-blockers. Variation
in drug use over time was also reduced. Objective improvement in clinical outcome was also
noted. Thus, practice guidelines improve the quality of care of patients with unstable angina.
(J Am Coll Cardiol 1999;34:1689–95) © 1999 by the American College of Cardiology
Clinical practice guidelines have been proposed as an
important means to improve “clinical effectiveness and
quality of care” (1–3). Medical organizations, health care
researchers, sponsors of health benefit plans and public
officials have all expressed interest in practice guidelines to
standardize treatment plans and to improve the cost effec-
tiveness of the US health care system (4,5). The presump-
tion for improved cost effectiveness is that clinical practice
guidelines present evidence-based treatment options clearly
and concisely. Physicians are then assumed to rapidly
assimilate the best evidence, streamline their management
and decision making and ultimately improve the effective-
ness of care for their patients.
The use of guideline reminders to implement practice
guidelines has previously been examined (6,7). Overhage
and McDonald (6) examined the use of preventive medicine
reminders given to physicians on daily rounds, suggesting
preventive care for eligible patients, and demonstrated the
ease with which guideline reminders can implement practice
guidelines and that intervention must be directed at the
physician responsible for point of care.
The Agency for Health Care Policy and Research
(AHCPR) published clinical practice guidelines for the
evaluation and diagnosis of unstable angina (8). A basic
tenet of the recommended policy is to match utilization of
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resources (i.e., drugs, intensive care, procedures, costs) to
the patient’s risk of adverse outcome. However, the best way
to implement these guidelines in clinical practice is uncer-
tain, and it was intentionally left by the AHCPR to the
individual physicians and hospitals to determine how best to
incorporate these concepts into practice. Thus, the current
study was designed to assess whether the use of clinical practice
guidelines alters the process of care in patients with unstable
angina as defined by the type, frequency and timeliness of
treatments received (so-called “process indicators”).
METHODS
Patient group. There were 484 patients with the diagnosis
of unstable angina consecutively admitted to the Rush
Presbyterian–St. Luke’s Medical Center in Chicago, Illi-
nois, between June 1, 1992 (the beginning of the clinical
data base) and April 1, 1994 (the month of publication of
the AHCPR clinical practice guidelines). Of the 484
patients admitted with this diagnosis, 338 were considered
by AHCPR definitions to have medium to high risk
unstable angina and were defined as group 1—the control
group. Between January 1, 1995 (the date of introduction of
a revised data base) and March 30, 1996, 225 patients
admitted with the diagnosis of unstable angina were
admitted consecutively to the medical center. Of the 225
patients admitted during this period, 181 were identified as
medium to high risk and were defined as group 2—the
study group admitted during the implementation of guideline
reminders.
Because of the lack of an emergency department (ED)
observation area during these periods, all patients with this
diagnosis were admitted to either the coronary care unit or
the coronary step-down unit. The AHCPR guidelines
defined patients as high risk for death or nonfatal myocar-
dial infarction when one of the following was present:
prolonged, ongoing (.20 min) rest pain, pulmonary edema,
angina with new or worsening mitral regurgitation, rest pain
with dynamic ST segment changes .1 mm, angina with an
S3 gallop, rales or hypotension. We modified this slightly by
adding another predictor—recent myocardial infarction
(,14 days), which we have determined to be a very
important predictor (9). The AHCPR guidelines defined
patients as medium risk when no high risk features were
present, but one of the following was present: resolved rest
angina, angina with dynamic T wave changes, nocturnal
angina, new-onset Canadian Cardiovascular Society class
III or IV angina in the past two weeks, Q waves or ST
segment depression .1 mm in multiple leads or age .65
years. Exclusion criteria included all patients with low risk
chest pain syndromes as defined by the AHCPR guidelines,
including increased angina of effort frequency, severity or
duration or angina provoked at lower work thresholds,
new-onset angina within two weeks to two months and a
normal electrocardiogram (ECG). Patients with cardiac
enzyme elevation ,12 h after admission consistent with a
non–Q wave myocardial infarction and those with chest
pain syndromes believed by their attending physician to not
be cardiac were also excluded.
Therapeutic intervention. The AHCPR guidelines’ in-
tended purpose was to define optimal diagnostic and man-
agement strategies for patients with unstable angina. These
included the use of intravenous (IV) nitroglycerin in the ED
for ongoing ischemia, the use of IV heparin in the ED for
all intermediate or high risk patients without contraindica-
tions and the use of aspirin and beta-blockers for all cardiac
patients without contraindications. These treatments repre-
sent process indicators of the quality of care. In January
1995, a medical grand rounds was conducted to inform the
medical house staff and attending physicians of the AHCPR
guidelines on unstable angina.
Also, during the intervention period (1995), a double-
sided two-page reminder was posted in the charts of all
patients admitted with unstable angina to the coronary care
unit or coronary care step down unit. Concurrently, a chest
pain assessment form was developed and introduced into
the ED. This form included prompts for indicated treat-
ment, and emergency physicians were made aware of guide-
line assessment through this form. All patients were treated
at the discretion of their attending physician.
Outcome assessment. The impact of clinical practice
guidelines on clinical treatments was determined through
evaluating treatments rendered before and after the institu-
tion of guideline reminders. Demographic variables, treat-
ment options and diagnostic/therapeutic procedures per-
formed were recorded for the two groups. These included
age, gender, hypertension, diabetes mellitus, tobacco use,
elevated cholesterol, previous medications, admission ECG
and treatments rendered such as IV heparin, IV nitroglyc-
erin, aspirin, IV or oral beta-blockers. Procedures incurred
by the groups included stress testing, diagnostic angiogra-
phy, angioplasty and coronary artery bypass graft surgery.
Major cardiac complications were defined by the occurrence
of either death or myocardial infarction after the first 12 h
of admission during the hospital period. Acute myocardial
infarction occurring as a complication of unstable angina
was diagnosed if new Q waves developed after the first 24 h
of hospital admission, the creatine kinase (CK) level ex-
ceeded 300 U/liter and the CK-MB fraction exceeded 0.05
after the first 12 h.
Data collection was performed by registered nurses
Abbreviations and Acronyms
AHCPR 5 Agency for Health Care Policy and
Research
CK 5 creatine kinase
ECG 5 electrocardiogram
ED 5 emergency department
IV 5 intravenous
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trained in data collection and was standardized through a
manual of operations that provided diagnostic definitions,
how to identify tests, treatments and complications. The
data were entered into a computerized data base directly by
the data collection nurse, and data quality assurance was
performed through electronic audits of selected missing or
out-of-range values. Chart audit was performed on 25% of
all charts for accuracy.
Statistical analysis. Univariate comparisons were made
using the chi-square test for categoric variables and the
Student t test for continuous variables. The primary end
points were frequency of use of aspirin, beta-blockers,
heparin and IV nitrates, as well as the timeliness of their use.
Secondary end points included coronary angiography and
revascularization and major cardiac complications. To de-
termine whether clinical confounders influenced the fre-
quency and timeliness of management, and to adjust the
effects of guidelines for these influences, multiple logistic
regression analyses were performed using as dependent
variables treatments and outcome variables found to be
different between the two groups. Independent variables
included guidelines group, all AHCPR predictors of com-
plications, coronary risk factors and evidence of previous
coronary artery disease. This analysis was performed in a
forward stepwise fashion using SAS software using an F
value of 4.0 and p ,0.05 to add a variable. Goodness-of-fit
was tested using 22 log of the likelihood. This result is
summarized as the overall p value of the model. In addition,
all variables entered in the stepwise regression model re-
duced the value of the Akaike Information Criterion. In this
way, we attempted to adjust for important clinical con-
founders.
RESULTS
Baseline characteristics. Table 1 compared the baseline
characteristics of groups 1 and 2. Although group 1 patients
were older, the incidence of hypercholesterolemia, diabetes,
family history, hypertension and smoking history were
similar between the two groups. The groups also had similar
frequencies of ST segment depression .1 mm and recent
myocardial infarction. Remote myocardial infarction (.2
weeks) was more frequent in group 1, although the rates of
previous revascularization and previous use of beta-blockers
and calcium channel blockers were higher in group 2.
Table 2. Treatments
Group 1 Group 2 p Value
ASA 298 (88%) 173 (96%) 0.009
IV beta-blocker 25 (7%) 13 (7%) 1.000
IV heparin 269 (80%) 155 (86%) 0.114
IV nitroglycerin on admission 116 (34%) 87 (43%) 0.003
IV nitroglycerin (at any time) 203 (60%) 93 (51%) 0.070
Oral beta-blocker 145 (43%) 91 (50%) 0.130
Data are presented as number (%) of patients.
ASA 5 aspirin; IV 5 intravenous.










Previous beta-blocker and calcium
channel blocker
153 (42%) 109 (60%) 0.002
Hypercholesterolemia 142 (42%) 90 (50%) 0.112
Diabetes 135 (40%) 63 (35%) 0.292
Family history 124 (37%) 84 (46%) 0.039
Hypertension 223 (66%) 118 (65%) 0.935
Smoking 156 (46%) 83 (46%) 1.000
Previous CABG 102 (30%) 69 (38%) 0.082
Previous PTCA 68 (20%) 64 (35%) 0.001
Previous MI* 131 (39%) 71 (22%) 0.001
ST segment depression 25 (7%) 16 (9%) 0.682
Recent MI† 19 (6%) 4 (2%) 0.132
Age (yrs) 68 6 13 63 6 16 0.001
*Previous myocardial infarction occurring .14 days before presentation. †Recent myocardial infarction within 14 days of
presentation. Data are presented as number (%) of patients or mean value 6 SD.
CABG 5 coronary artery bypass graft surgery; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty.
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Treatment in the hospital (process indicators). Medical
treatments and interventions are summarized in Tables 2
and 3, respectively. Group 2 patients received aspirin and IV
nitroglycerin for the index pain more frequently than did
group 1 patients. The use of IV beta-blockers was similar in
both groups. Group 2 had a 7% increase in the use of
heparin and a 16% increase in the use of oral beta-blockers
as compared with group 1, although neither of these was
statistically significant. This also included a 32% increase in
a new beta-blocker usage (p 5 0.099), which was also not
statistically significant.
The timeliness of drug administration is demonstrated in
Figure 1. The use of beta-blockers (p 5 0.008, panel A) and
aspirin (panel C, p 5 0.090) was instituted earlier in group
2 patients. Intravenous heparin was unaffected. Also, the
variation over the time of the study in the use of beta-
blocker and aspirin (Fig. 2 and 3) was reduced after
guideline reminders (group 2) were introduced.
Although not a primary end point, coronary angiography
was used more frequently in group 2 patients, whereas
the rates of coronary artery bypass graft surgery and percu-
taneous transluminal coronary angioplasty were similar be-
tween the groups. However, coronary angiography was
performed earlier in group 2 patients (Fig. 1, panel B, p 5
0.001).
Table 3. Interventions
Group 1 Group 2 p Value
CABG 50 (15%) 24 (13%) 0.731
PTCA 98 (29%) 43 (24%) 0.240
Coronary angiogram 196 (58%) 128 (71%) 0.006
Data are presented as number (%) of patients. Abbreviations as in Table 1.
CABG 5 coronary artery bypass grafting; PTCA 5 percutaneous transluminal
coronary angioplasty.
Figure 1. Frequency of the use of oral beta-blocker (A), coronary angiogram (B), aspirin (ASA), (C) and IV heparin (D) as a function
of the hospital day on which they were started or performed. Day 0 5 admission day.
Figure 2. The use of beta-blockers over the study periods of both
groups 1 (control) and 2 (guideline reminders). The bold vertical
line indicates the beginning of the test period. The upper
horizontal line inside the box represents the median value, and the
lower horizontal line the mean value. The bottom of each box
plot represents the 25th and 75th percentiles. The whiskers at the
end of the horizontal lines represent the 95th percentiles. Solid
circles 5 before guideline reminders were instituted; open cir-
cles 5 after guideline reminders were instituted; rectangular
boxes 5 box plots before and after guideline reminders were
instituted.
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To determine if any confounders explained the differ-
ences in treatment between the two groups, multiple logistic
regression analyses were performed for the following
evaluations and treatments that we found to be different
between the two groups: coronary angiography at any
time during the hospital period, coronary angiography
within 24 h, use of an oral beta-blocker within 24 h and use
of aspirin and IV nitroglycerin on admission. These are
summarized in Table 4. In each case the guideline group
was associated with greater use of a treatment or test with
odds ratios varying between 2.1 for an angiogram at any
time during the hospital period to 2.66 for the use of aspirin.
Clearly, other clinical factors were associated with a greater
or earlier clinical use of a test or treatment. Family history,
tobacco history, recent myocardial infarction (,14 days)
and recurrent angina were associated with greater use of
coronary angiography. Previous coronary artery bypass
graft surgery and recurrent angina were associated with
greater use of IV nitroglycerin at the time of hospital
admission.
Patient outcomes. Patient outcomes are summarized in
Table 5. Group 2 patients had a lower incidence of the
combined end point of myocardial infarction or death (67%
reduction), recurrent angina (46% reduction) and serious
ventricular dysrhythmia (92% reduction). Table 6 summa-
rizes multiple logistic regression analysis for major cardio-
vascular outcomes. Two composite outcomes were used:
1) myocardial infarction, death, heart failure, ventricular
tachycardia or ventricular fibrillation; and 2) any of the
aforementioned composite outcomes or recurrent angina.
Both composites were less frequent in the guideline group
as compared with the control group, even after adjusting
for other potential confounders. Other clinical variables
associated with poor outcomes are also summarized in
Table 6.
DISCUSSION
This study demonstrates that clinical practice guidelines can
beneficially alter treatment patterns in unstable angina.
Specifically, we determined that intensive medical treatment
was more frequently and more uniformly offered after
Figure 3. The use of aspirin (ASA) over the study periods of both
groups 1 (control) and 2 (guideline reminders). See Figure 2 for
explanation of symbols.
Table 4. Multiple Logistic Regression Analysis of Invasive Evaluation and Medical Treatment in Unstable Angina
Dependent Variable Independent Variable OR p Value
Model
p Value
Angiogram Guideline group 2.10 0.0002 0.0001
Family history 1.60 0.019
Tobacco history 0.68 0.050
Recent MI 3.20 0.048
Recurrent angina 2.15 0.0001
Angiogram within 24 h Guideline group 2.30 0.0003 0.0003
Oral beta-blocker within 24 h Guideline group 2.12 0.043 0.0018
T wave inversion 2.62 0.030
Aspirin Guideline group 2.66 0.015 0.0024
History of renal failure 0.37 0.034
IV nitroglycerin or admission Guideline group 2.30 0.001 0.0001
Previous CABG 1.60 0.016
Recurrent angina 1.48 0.044
OR 5 multivariate odds ratio; model p value indicates goodness-of-fit of overall model based on 22 log of likelihood; other abbreviations as in Table 1.
Table 5. Complications
Group 1 Group 2 p Value
Myocardial infarction 24 (7%) 5 (3%) 0.064
Death 6 (2%) 1 (1%) 0.452
Myocardial infarction
or death
30 (9%) 6 (3%) 0.028
Recurrent angina 182 (54%) 53 (29%) 0.001
VT/VF 42 (12%) 3 (1%) 0.001
Data are presented as number (%) of patients.
VT/VF 5 ventricular tachycardia or fibrillation.
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clinical practice guidelines were adopted and introduced to
the medical staff by being posted on patients’ charts as a
reminder. This pattern of intensive treatment suggests that
patients with medium or higher risk unstable angina re-
ceived better anti-anginal therapy at hospital admission, in
accordance with AHCPR guidelines, than they did before
publication of the guidelines. Furthermore, less variation in
the use of medical treatment was also noted after the
guidelines were introduced, demonstrating that the effect of
our method of introduction of clinical practice guidelines
occurred quickly and was sustained. Finally, the early and
more frequent use of these treatments in this preliminary
study was associated with fewer ischemic-related complica-
tions, showing for the first time that guidelines may impact
clinical outcome in acute coronary syndromes. Although
this finding requires further validation because of the small
sample size, the potential for selection bias was addressed by
multivariate analysis, which confirmed the effect of guide-
lines even after adjusting for other potential clinical con-
founders.
Industry definitions of quality of care focus on reducing
variation in the processes of care to improve cost effective-
ness (1). Medical practice guidelines are an attractive tool
because, in the best of cases, they provide a coherent
sequenced set of recommendations based on the best clinical
evidence to achieve the best outcomes (3,10). However, one
major limitation to date has been the failure to demonstrate
the value of clinical practice guidelines on improving quality
of practice or improving outcome. In fact, one meta-analysis
has suggested that primary care guidelines do not improve
outcome (11), and another study suggested that the guide-
lines might have contributed to extra cost, leading one
expert (12) to conclude that “clinical practice guidelines
were on trial.” However, a more recent meta-analysis that
looked at a variety of interventions found not only positive
effects of the guidelines but also that the guideline remind-
ers, as used in this study, were one of the most effective ways
to implement practice guidelines, resulting in significant
practice changes and improved outcomes (13).
Although few clinical practice guidelines have been sys-
tematically evaluated for effectiveness in general, Weingar-
ten et al. (14,15) did examine practice guidelines in the
setting of patients being admitted to rule out myocardial
infarction (many of whom had unstable angina). They
examined the benefit, risk and costs of implementing a
practice guideline for patients with chest pain syndromes
who were considered low risk. Their results revealed that
patients with chest pain who were considered low risk for a
complication could be treated effectively with lower costs
and without compromise in patient outcome or satisfaction.
Notably, the impact and effectiveness of recent AHCPR
guidelines on unstable angina evaluation and treatment have
not been studied.
The current AHCPR guidelines on unstable angina (8)
consists of over 100 pages of material, including over 100
recommendations and over 120 references, posing a signif-
icant challenge to health care deliverers to systematically
implement the guidelines, particularly when it may affect
over 200 physicians in a single center as it does in our
institution. The approach we used was rather comprehen-
sive and involved multiple strategies to enhance physician
compliance, because previous reviews have suggested that a
multimodality approach to implementation may be most
effective (6,16). The use of a reminder system, in particular,
was chosen because of ease of its implementation, its focus
on providing useful information at the point of care and its
respect for physician autonomy.
The primary end points used in this study were the
proven treatments in unstable angina as recommended by
the guidelines. These treatments serve as process indicators
of quality of care. Because the guidelines also suggested that
invasive and conservative strategies of evaluation were
equivalent, less focus was placed on the type of strategy
employed and more emphasis was placed on the timeliness
of the chosen evaluation strategy. However, the AHCPR
guidelines recommends coronary angiography in the pres-
ence of high risk features and recurrent angina (an inclusion
criteria for this study). The use and choice of revasculariza-





Ratios 95% CI p Value
Model
p Value
Myocardial infarction or death Guideline group 0.266 0.104–0.680 0.0100 0.0001
or CHF or VT or VF Previous CABG 2.720 1.315–5.626 0.0058
Coronary angiography 3.749 1.455–9.662 0.0058
PTCA 4.486 2.013–9.999 0.0001
CABG 4.381 1.739–11.036 0.0001
Myocardial infarction or death Guideline group 0.196 0.109–0.351 0.0001 0.0001
or CHF or VT or VF or Age 0.977 0.959–0.995 0.0152
recurrent angina Coronary angiography 2.599 1.535–4.400 0.0001
PTCA 2.066 1.190–3.586 0.0068
IV nitroglycerin 1.825 1.100–3.028 0.0191
CHF 5 congestive heart failure; CI 5 confidence interval; VT or VF 5 ventricular tachycardia or fibrillation; other abbreviations as in Table 1.
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tion, which depended previously on coronary anatomy, were
not a prime focus of this intervention.
Study limitations. The major limitations of the study are
the absence of a concurrent comparison group and the
nonrandomized nature of patient enrollment. To assess a
difference in treatment patterns, separate periods of patient
enrollment were necessary to avoid the “knowledge” bias,
which may occur as physicians are repeatedly exposed to the
guideline reminders. This knowledge bias may alter routine
treatment patterns and subsequently greatly skew results.
Several experts (12,16) have commented that the reference
standard for a study such as ours, which is a behavioral one,
is not necessarily a randomized clinical trial. Randomized,
controlled trials would be particularly vulnerable to Haw-
thorne effects (i.e., the knowledge that one is in a trial can
contaminate the experimental group), systematically expos-
ing it to factors unrelated to guidelines that were not
experienced by the control group (12).
In an attempt to address this issue, Hayward et al. (12) listed
criteria for the quality of studies of clinical practice guidelines,
besides randomization, most of which are fulfilled in this study.
Furthermore, using a grading system proposed by Johnston et
al. (17), our study design, despite not being randomized, would
fall close to the median quality score of the 28 studies reviewed
recently by that group. Furthermore, to adequately test the
effectiveness of a practice guideline, one attempts to study an
entire population rather than a small targeted group. This
allows a determination of the amount of variation in treatment,
which may exist in general, when treating such patients. Thus,
study designs including separate control and study groups
enrolled consecutively seemed best suited to optimize the effect
that clinical guidelines have on treatment patterns. Further-
more, we used multiple logistic regression analysis to identify
important clinical confounders independently influencing tem-
poral changes in clinical practice and to assess their relative
importance. Although some clinical confounders were identi-
fied, the use of guidelines more than doubled the odds of using
important medical therapy and early coronary angiography,
and was associated with fewer clinical events independent of
any other identified clinical factor.
In summary, clinical practice guidelines in unstable an-
gina, when implemented using an effective means, had a
substantial impact on the evaluation and management of
patients with unstable angina and were associated with
better patient outcome.
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